Komorizono Y, Hosoyamada K, Imamura N, et al. - In patients with type 2 diabetes mellitus (T2DM), the researchers sought to validate the impact of linagliptin, an oral dipeptidyl peptidase‐4 inhibitor, on nonalcoholic fatty liver disease (NAFLD). In total, 50 patients with NAFLD and T2DM who were treated with metformin were randomly allocated (1:1) to metformin add‐on linagliptin (L‐group) or increased metformin (M‐group) for 52 weeks. In contrast to the M-group, the L-group showed no statistical decrease in HS, although hepatic steatosis (HS) changes were significantly associated with decreased liver enzymes in both groups. In M‐group, body weight was significantly decreased, but not in the L‐group. Compared with M‐group, serum leptin levels were significantly increased in the L‐group, and were associated with the body weight changes in whole samples. The adverse events between the two groups were not different. L‐group had a safe profile but not superiority to M‐group in lowering HS.